Evidence map›Paper›PMID 38954846›Full record

ArticleThe oncologist2025

Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.

Wanwan Cheng, Ting Xu, Lu Yang, Naimeng Yan, Jie Yang, Shencun Fang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wanwan ChengDepartment of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
Ting XuDepartment of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
Lu YangThe Genetic Analysis Department, YuceBio Technology Co., Ltd., Shenzhen, China.
Naimeng YanThe Genetic Analysis Department, YuceBio Technology Co., Ltd., Shenzhen, China.
Jie YangThe Genetic Analysis Department, YuceBio Technology Co., Ltd., Shenzhen, China.
Shencun FangDepartment of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-4223-5428

Funding

"Six one projects" in Jiangsu Province LGY2019006
6 · The paper itself

Abstract

With the widespread use of next-generation sequencing (NGS) for solid tumors, mesenchymal-to-epithelial transition factor (MET) rearrangement/fusion has been confirmed in multiple cancer types. MET amplification and MET exon 14 skipping mutations induce protein autophosphorylation; however, the pathogenic mechanism and drug sensitivity of MET fusion remain unclear. The following report describes the clinical case of a patient diagnosed with squamous lung cancer bearing a TFG-MET gene fusion. In vitro assays demonstrated MET phosphorylation and oncogenic capacity due to the TFG-MET rearrangement, both of which were inhibited by crizotinib treatment. The patient was treated with crizotinib, which resulted in sustained partial remission for more than 17 months. Collectively, cellular analyses and our case report emphasize the potential of MET fusion as a predictive biomarker for personalized target therapy for solid tumors.

Indexed as

CrizotinibLung NeoplasmsProto-Oncogene Proteins c-metCarcinoma, Squamous CellHumansMaleMiddle AgedOncogene Proteins, FusionPhosphorylationProtein Kinase InhibitorsVesicular Transport ProteinsCrizotinibMET protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-metTFG protein, humanVesicular Transport ProteinsbiomarkercrizotinibMET rearrangementNSCLCsensitive

Identifiers

PMID38954846
PMCPMC11783276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.